A new AI-enabled disease management tool in China aims to improve the lives of millions of patients with heart failure.

Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.

From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.

The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.